Evidence map›Paper›PMID 28111575›Full record

ArticleFrontiers in immunology2016

Pro-inflammatory-Related Loss of CXCL12 Niche Promotes Acute Lymphoblastic Leukemic Progression at the Expense of Normal Lymphopoiesis.

Juan Carlos Balandrán, Jessica Purizaca, Jennifer Enciso, David Dozal, Antonio Sandoval, Elva Jiménez-Hernández, Leticia Alemán-Lazarini, Vadim Perez-Koldenkova, Henry Quintela-Núñez Del Prado, Jussara Rios de Los Ríos and 4 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 51 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Biology and Therapeutic Properties of Mesenchymal Stem Cells in Leukemia.International journal of molecular sciences · 2024
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 2 countries.

Juan Carlos BalandránOncology Research Unit, Mexican Institute for Social Security, Mexico City, Mexico; Molecular Biomedicine Program, CINVESTAV, IPN, Mexico City, Mexico.
Jessica PurizacaOncology Research Unit, Mexican Institute for Social Security , Mexico City , Mexico.
Jennifer EncisoOncology Research Unit, Mexican Institute for Social Security, Mexico City, Mexico; Biochemistry Sciences Program, Universidad Nacional Autónoma de Mexico, Mexico City, Mexico.
David DozalHospital para el Niño, Instituto Materno Infantil del Estado de México , Toluca , México.
Antonio SandovalHospital para el Niño, Instituto Materno Infantil del Estado de México , Toluca , México.
Elva Jiménez-HernándezServicio de Hematología, Hospital Pediátrico Moctezuma, SSA , Mexico City , Mexico.
Leticia Alemán-LazariniDepartment of Molecular Biomedicine, CINVESTAV , Mexico City , Mexico.
Vadim Perez-KoldenkovaLaboratorio de Microscopía, Centro de Instrumentos, Coordinación de Investigación en Salud, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social , Mexico City , México.
Henry Quintela-Núñez Del PradoUMAE "Dr. Victorio de la Fuente Narvaez", Instituto Mexicano del Seguro Social , Mexico City , México.
Jussara Rios de Los RíosOncology Research Unit, Mexican Institute for Social Security, Mexico City, Mexico; Biochemistry Sciences Program, Universidad Nacional Autónoma de Mexico, Mexico City, Mexico.
Héctor MayaniOncology Research Unit, Mexican Institute for Social Security , Mexico City , Mexico.
Vianney Ortiz-NavarreteMolecular Biomedicine Program, CINVESTAV, IPN , Mexico City , Mexico.
Monica L GuzmanDivision of Hematology and Medical Oncology, Weill Cornell Medicine , New York, NY , USA.
Rosana PelayoOncology Research Unit, Mexican Institute for Social Security , Mexico City , Mexico.
Mexican Social Security Institute · MXCenter for Research and Advanced Studies of the National Polytechnic Institute · MXInstituto de Salud del Estado de México · MXCornell University · USHospital Pediátrico Moctezuma · MXUniversidad Nacional Autónoma de México · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pediatric oncology, notably childhood acute lymphoblastic leukemia (ALL), is currently one of the health-leading concerns worldwide and a biomedical priority. Decreasing overall leukemia mortality in children requires a comprehensive understanding of its pathobiology. It is becoming clear that malignant cell-to-niche intercommunication and microenvironmental signals that control early cell fate decisions are critical for tumor progression. We show here that the mesenchymal stromal cell component of ALL bone marrow (BM) differ from its normal counterpart in a number of functional properties and may have a key role during leukemic development. A decreased proliferation potential, contrasting with the strong ability of producing pro-inflammatory cytokines and an aberrantly loss of CXCL12 and SCF, suggest that leukemic lymphoid niches in ALL BM are unique and may exclude normal hematopoiesis. Cell competence

Indexed as

acute lymphoblastic leukemiaCXCL12leukemic nichespro-inflammatory bone marrowtumor microenvironment

Identifiers

PMID28111575
PMCPMC5216624
OpenAlexW2569807751

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.